[ Back to EurekAlert! ] Public release date: 3-Jul-2012
[ | E-mail Share Share ]

Contact: Sam Wong
sam.wong@imperial.ac.uk
44-207-594-2198
Imperial College London

Polio vaccination programs not reaching enough children in Afghanistan and Pakistan

New, more effective vaccines are struggling to have an impact in the drive to eradicate polio in Afghanistan and Pakistan because not enough children are being vaccinated, according to a study published in the Lancet medical journal today. Sharp declines in vaccine uptake led to a rise in the number of new infections between 2006 and 2011, even though new vaccines introduced during this time have proven to be more effective against the main circulating strain of the virus.

Poliovirus exists in three strains, with type 1 the most prevalent and type 2 unseen anywhere in the world since 1999. It mainly affects children under five and causes paralysis in about one in 200 cases. In most parts of the world it has been eliminated by sustained vaccination programmes in the late 20th century. Afghanistan and Pakistan are among only three countries along with Nigeria that have never managed to eliminate polio.

Since it was launched in 1988, the Global Polio Eradication Initiative (GPEI) spearheaded by national governments, the World Health Organization (WHO), Rotary International, the US Centers for Disease Control and Prevention (CDC) and UNICEF - has relied on mass campaigns using the trivalent oral poliovirus vaccine, which contains all three types of the virus,. However, the presence of the type 2 strain in the trivalent vaccine makes it less effective against the other types. In 2005, monovalent vaccines of types 1 and 3 were introduced by the GPEI and in 2009 a bivalent vaccine containing both types was first used.

Scientists from Imperial College London and the WHO assessed the effect of immunisation campaigns in the Afghanistan and Pakistan by analysing data collected by national surveillance programmes. They also assessed the effectiveness of the three varieties of polio vaccine against the predominant type 1 strain of the virus.

The study found that the monovalent vaccine was more effective than the trivalent vaccine against type 1 poliovirus. The bivalent vaccine was comparable in effectiveness to the monovalent vaccine. The difference between the bivalent and trivalent vaccines was not large enough to be statistically significant.

In 2006 over 80% of children in Afghanistan and Pakistan aged 0-2 years old received four doses or more of vaccine. However, vaccine coverage in southern Afghanistan and parts of Pakistan, including Balochistan and the Federally Administered Tribal Areas (FATA) declined from 2006 to 2011. Although the impact was partially offset by the use of the more effective vaccines, this resulted in significantly lower population immunity levels, leading to an increase in cases over that time frame. In 2011 there were 198 cases in Pakistan and 80 cases in Afghanistan compared with 40 cases in Pakistan and 31 in Afghanistan in 2006.

This analysis prompted a major shift in approaches in 2012 in both countries, to address the underlying challenges which prevent children from having access to polio vaccines. Both countries are this year implementing national polio emergency action plans, involving measures such as increasing technical support to the worst-performing areas; creating accountability mechanisms for district-level leadership; and engaging with communities to increase demand for immunisation.

"Our findings show it's not just small pockets where vaccine coverage decreased from 2006 to 2011," said Dr Kath O'Reilly, from the Medical Research Council (MRC) Centre for Outbreak Analysis and Modelling at Imperial College London, who led the study. "The new vaccines appear to be more effective than the trivalent vaccine, which offers encouragement that polio eradication is achievable. But the best vaccine in the world will not work unless it reaches the children its intended to protect. So it's vitally important that vaccine coverage is considerably improved in 2012 through better campaigns and routine programmes if we're to finally eradicate polio globally."

###

The study was funded by the WHO, the Royal Society and the Medical Research Council.

For further information please contact:

Sam Wong
Research Media Officer
Imperial College London
Email: sam.wong@imperial.ac.uk
Tel: +44(0)20 7594 2198
Out of hours duty press officer: +44(0)7803 886 248

Notes to editors

1. Reference: KM O'Reilly et al. 'The effect of mass immunisation campaigns and new oral poliovirus vaccines on the incidence of poliomyelitis in Pakistan and Afghanistan, 2001-11: a retrospective analysis.' The Lancet, 4 July 2012.

2. About Imperial College London

Consistently rated amongst the world's best universities, Imperial College London is a science-based institution with a reputation for excellence in teaching and research that attracts 14,000 students and 6,000 staff of the highest international quality. Innovative research at the College explores the interface between science, medicine, engineering and business, delivering practical solutions that improve quality of life and the environment - underpinned by a dynamic enterprise culture.

Since its foundation in 1907, Imperial's contributions to society have included the discovery of penicillin, the development of holography and the foundations of fibre optics. This commitment to the application of research for the benefit of all continues today, with current focuses including interdisciplinary collaborations to improve global health, tackle climate change, develop sustainable sources of energy and address security challenges.

In 2007, Imperial College London and Imperial College Healthcare NHS Trust formed the UK's first Academic Health Science Centre. This unique partnership aims to improve the quality of life of patients and populations by taking new discoveries and translating them into new therapies as quickly as possible.

Website: www.imperial.ac.uk
Twitter: www.twitter.com/imperialspark
Podcast: www.imperial.ac.uk/media/podcasts

3. For almost 100 years the Medical Research Council has improved the health of people in the UK and around the world by supporting the highest quality science. The MRC invests in world-class scientists. It has produced 29 Nobel Prize winners and sustains a flourishing environment for internationally recognised research. The MRC focuses on making an impact and provides the financial muscle and scientific expertise behind medical breakthroughs, including one of the first antibiotics penicillin, the structure of DNA and the lethal link between smoking and cancer. Today MRC funded scientists tackle research into the major health challenges of the 21st century. www.mrc.ac.uk



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.